Anti-Human IL-6 (Sarilumab) (IVMB0457)

(No reviews yet) Write a Review
SKU:
IVMB0457
Antibody Type:
Biotinylated Biosimilar
Modifications:
Biotinylated
Disease Area:
Inflammatory Diseases
Disease Area:
Autoimmune Disorders
Applications:
SPR, ELISA, Drug Development, Inflammation Assays, Inflammatory Response Assays, Pharmacokinetics

Description

system_update_altDatasheetsystem_update_altMSDS
Product Name:Anti-Human IL-6 (Sarilumab)
SKU:IVMB0457
Size:50 µg, 100 µg
Antibody Type:Biosimilar Recombinant Human Monoclonal Antibody
Clone:Hu137
Target:IL-6
Isotype:Human IgG1κ
Host Species:Human
Reactivity:Human
Applications:ELISA
Expression Host:HEK-293 Cells
FC Effector Activity:Active
Synonyms:Interleukin-6, CDF; HGF; HSF; BSF2; BSF-2; IFNB2; IFN-beta-2
Product Concentration:0.5 mg/ml
Applications and Recommended Usage:FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
ELISA
Antigen Distribution:IL-6R is ubiquitously expressed.
Formulation:This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Specificity:This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Sarilumab. Sarilumab binds to the transmembrane and soluble forms of the IL-6 receptor. This product is for research use only.
Additional Applications Reported In Literature:FA
Additional Reported Applications For Relevant Conjugates:BNIHC (Paraffin)IHC (Frozen)WB

IL-6 and its signaling pathway play a part in immune response regulation, inflammation, and hematopoiesis.2 Sarilumab is a research-grade recombinant human monoclonal IL-6 receptor antagonist. It specifically binds to both the transmembrane and soluble forms of the IL-6 receptor, thus inhibiting IL-6–mediated cis and trans-signaling in a dose-dependent manner. Therapeutic Sarilumab, also known by the trade name Kevzara, is currently used to treat Rheumatoid Arthritis1, however, as of March 2020, The Feinstein Institute of Northwell Health publicized a study on "a human antibody that may prevent the activity" of IL-6 for the treatment of COVID-19. Anti-Human IL-6 (Sarilumab) utilizes the same variable regions from the therapeutic antibody Sarilumab making it ideal for research projects.

Regulatory Status:Research Use Only (RUO). Non-Therapeutic.
Storage and Handling:This biotinylated antibody is stable when stored at 2-8°C.Do not freeze.
Research Area:Biosimilars

0 Reviews

View AllClose

Related Products